Paris, France, Tuesday February 28, 2023, 5:45 pm CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2023.


Information Date*
2022 Full-Year Financial Update and Statements March 24, 2023
2023 1Q Cash Position April 20, 2023
Annual General Meeting May 16, 2023
2023 First-Half Financial Update and Statements July 26, 2023
2023 3Q Cash Position October 26, 2023
2023 4Q Cash Position January 25, 2024

* This financial calendar is provided for information only and may be subject to changes. The Company’s updated financial calendar is available on its corporate website.